Janux Therapeutics (JANX) Total Liabilities (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Total Liabilities data on file, last reported at $86.7 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $86.7 million, up 126.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.7 million (up 126.33% YoY), and the FY2025 annual result was $44.7 million, up 15.51% from the prior year.
• Total Liabilities grew to $86.7 million in Q1 2026 per JANX's latest filing, from $44.7 million in the prior quarter.
• Over five years, Total Liabilities peaked at $86.7 million in Q1 2026 and troughed at $12.5 million in Q1 2022.
• A 5-year average of $41.4 million and a median of $41.6 million in 2022 frame the typical range for Total Liabilities.
• On a YoY basis, Total Liabilities climbed as much as 245.45% in 2022 and fell as far as 25.38% in 2022.
• A 5-year view of Total Liabilities shows it stood at $43.3 million in 2022, then declined by 16.67% to $36.1 million in 2023, then climbed by 7.42% to $38.7 million in 2024, then grew by 15.51% to $44.7 million in 2025, then jumped by 93.75% to $86.7 million in 2026.
• Business Quant data shows JANX's Total Liabilities at $86.7 million in Q1 2026, $44.7 million in Q4 2025, and $48.2 million in Q3 2025.